1. Scrip
  2. >>Focus On Asia
  3. >>India

Ranitidine Recall Dents GSK India, Which Mulls Plant Sale

 
• By Anju Ghangurde

GlaxoSmithKline India’s Vemgal plant, which entailed a large investment outlay, may be put on the block as part of a review of assets impacted by the recall of ranitidine over NDMA impurity concerns. The site, which has “all relevant approvals”, has not made commercial supplies yet.

Blocks
Ranitidine Recall-Related Issues Hurt GSK India • Source: Shutterstock

GlaxoSmithKline PLC may consider divesting its pharmaceutical manufacturing facility in Vemgal, Karnataka, the first such greenfield site the UK multinational had built globally over the recent past, as it reviews the fallout from the recall of ranitidine products on all its related assets in India.

The Vemgal site, which entailed an investment of over INR10bn ($141m), was apparently focused to a large extent on ranitidine production, and the uncertain outlook for the product caused by concerns over the probable cancer-causing

More from India

More from Focus On Asia